The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2012 Release

December 25, 2012 Approval of a Once-Monthly Formulation of Risedronate Sodium Hydrate,an Antiosteoporotic Agent in Japan
December 18, 2012 U.S. SUBSIDIARY EISAI INC. DIVESTS U.S. RIGHTS FOR ANTINEOPLASTIC GLIADEL® WAFER TO ARBOR PHARMACEUTICALS, INC.
December 14, 2012 EISAI AND UCL FORM MAJOR DRUG DISCOVERY ALLIANCE TO DEVELOP NEW THERAPEUTICS FOR NEUROLOGICAL DISEASES
December 13, 2012 EISAI NORTH CAROLINA PLANT ENTERS INTO STRATEGIC MANUFACTURING ALLIANCE AGREEMENT WITH U.S.'S BIOGEN IDEC
December 11, 2012 SCOTTISH MEDICINES CONSORTIUM APPROVES AMPA RECEPTOR ANTAGONIST FYCOMPA® AS ANTIEPILEPTIC TREATMENT UNDER NATIONAL HEALTH SERVICE SCOTLAND
December 10, 2012 EISAI RECEIVES SIX-MONTH PEDIATRIC EXCLUSIVITY FOR PROTON-PUMP INHIBITOR ACIPHEX® IN THE U.S.
December 7, 2012 PHASE III STUDY (STUDY 301) RESULTS OF ANTICANCER AGENT HALAVEN® VERSUS CAPECITABINE IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER PRESENTED AT 2012 SABCS
November 30, 2012 PEDIATRIC NDA FOR PROTON-PUMP INHIBITOR ACIPHEX® GRANTED PRIORITY REVIEW IN THE U.S.
November 29, 2012 EISAI TO PRESENT NEW RESEARCH ON HALAVEN® AT 35TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
November 20, 2012 EISAI TO OFFER DONATIONS TO HURRICANE SANDY NEW JERSEY RELIEF FUND AND AMERICAN RED CROSS
October 29, 2012 Abbott Japan and Eisai Clear All-Case Surveillance Condition for Approval of Humira®, a Fully Human Anti-TNF-α Monoclonal Antibody, in the Treatment of Crohn's Disease
October 25, 2012 EISAI SIGNS GLOBAL AGREEMENT WITH FUNDAÇÃO OSWALDO CRUZ TO BEGIN DEVELOPMENT OF NEW MEDICINES AND VACCINES FOR MALARIA AND NEGLECTED TROPICAL DISEASES
October 23, 2012 U.S. FDA APPROVES EISAI'S AMPA RECEPTOR ANTAGONIST FYCOMPA™ (PERAMPANEL) AS ADJUNCTIVE TREATMENT FOR PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 12 AND OLDER
October 10, 2012 EISAI GROUP TO TRANSFORM ITS PRODUCT CREATION STRUCTURE TO REFLECT FOCUS ON PERSONALIZED MEDICINE
September 27, 2012 EISAI DEMAND CHAIN SYSTEMS (EDCS) TO UNDERGO TRANSFORMATION WITH THE INTRODUCTION OF A NEW GLOBAL PRODUCTION STRUCTURE
September 25, 2012 EISAI OPENS NEW SOLID DOSE GLOBAL MANUFACTURING LINE FOR ANTIEPILEPTIC AGENT FYCOMPA® AT ITS PRODUCTION PLANT IN HATFIELD, U.K.
Ceremony attended by Rt Hon. David Willetts, Minister of State for Universities and Science
September 25, 2012 Eisai and Santen Enter into Option Agreement for New Ophthalmic Drugs
September 25, 2012 EISAI ANNOUNCES LAUNCH OF CHOCOLA BB® HYPER, A NUTRITIONAL SUPPLEMENT DRINK FOR THE RELIEF OF EXTREME FATIGUE AND EXHAUSTION
Contains 13 active ingredients effective in combatting fatigue symptoms
September 13, 2012 EISAI ANNOUNCES LAUNCH OF AMPA RECEPTOR ANTAGONIST FYCOMPA® FOR THE TREATMENT OF EPILEPSY
Europe first region in the world to gain access to this new first-in-class therapy
September 12, 2012 EISAI PARTNERS WITH THE SABIN VACCINE INSTITUTE IN AN EFFORT TO DEVELOP VACCINES FOR NEGLECTED TROPICAL DISEASES
September 12, 2012 EISAI ANNOUNCES LAUNCH OF CRYSTAL VEIL® MASK BOKIN 24, A NEW 24-HOUR MASK SPRAY THAT CONTAINS THE LONG-ACTING ANTIMICROBIAL AGENT ETAK®
Helps Prevent the Adherence of Viruses and Bacteria to Face Masks
September 12, 2012 EISAI ANNOUNCES LAUNCH OF CRYSTAL VEIL®α, A TOPICAL NASAL GEL THAT BLOCKS VIRUSES FROM ENTERING THE BODY THROUGH THE NOSE
September 11, 2012 Companies Announce Reimbursement Approval and Launch of CoaguChek® XS Personal, a Coagulation Analyzer for Patient Self-Testing
- Offers Improved Convenience for Left Ventricular Assist System (LVAS) Patients on Anticoagulation Therapy -
September 11, 2012 EISAI ANNOUNCES LAUNCH OF ANTI-RHEUMATIC AGENT CARERAM®
September 7, 2012 EISAI RECEIVES APPROVAL TO MARKET ANTICANCER AGENT HALAVEN® IN AUSTRALIA
September 3, 2012 EISAI RECEIVES APPROVAL FOR ANTICANCER AGENT HALAVEN® IN SOUTH KOREA
August 31, 2012 Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
August 30, 2012 EISAI SUBMITS APPLICATION IN JAPAN FOR ANTIEPILEPTIC AGENT RUFINAMIDE FOR LENNOX-GASTAUT SYNDROME
August 20, 2012 EISAI RECEIVES ORPHAN DRUG DESIGNATION FOR ANTICANCER AGENT LENVATINIB IN JAPAN
August 20, 2012 EISAI ANNOUNCES LAUNCH OF CHOCOLA BB® Fe CHARGE,
A DELICIOUS, EASY-TO-DRINK IRON SUPPLEMENT
August 15, 2012 MORPHOTEK OPENS PILOT ANTIBODY MANUFACTURING PLANT
~ Facility Will Help Accelerate Early-Stage Clinical Trials of Biologics ~
August 10, 2012 Abbott Japan and Eisai Receive Approval to Market the Fully Human Anti-TNF-Alpha Monoclonal Antibody Humira® (adalimumab) For the Inhibition of Structural Damage of Joints in Patients with Rheumatoid Arthritis
August 1, 2012 CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
July 30, 2012 KAN RESEARCH INSTITUTE TO RELOCATE TO NEW FACILTY INSIDE INTERNATIONAL STRATEGIC INNOVATION ZONE
July 30, 2012 EISAI RECEIVES ANTIOBESITY AGENT BELVIQ® (lorcaserin HCl) NDA FROM ARENA PHARMACEUTICALS
July 27, 2012 EUROPEAN COMMISSION APPROVES EISAI'S AMPA RECEPTOR ANTAGONIST FYCOMPA® (PERAMPANEL)
-- First Approval for the New Class of Partial Epilepsy Treatment in the World --
July 24, 2012 EISAI ANNOUNCES FULL-SCALE LAUNCH OF CHOCOLA BB® SPARKLING WHITE GRAPE FLAVOR
- Contains Five Ingredients That Help Women Bring Out Their Beauty From Within -
July 19, 2012 EISAI PRESENTS FIRST CLINICAL DATA FOR BACE INHIBITOR E2609 AT ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2012
July 17, 2012 EISAI ENTERS RESEARCH COLLABORATION WITH VERASTEM, INC. FOR SMALL MOLECULE WNT INHIBITORS
--Partnership Based on Open Innovation That Leverages Eisai's Natural Product Chemistry-Based Drug Discovery Platform--
July 13, 2012 EISAI TO PRESENT FIRST CLINICAL DATA FOR BACE INHIBITOR E2609 AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2012
July 10, 2012 EISAI ANNOUNCES PRELIMINARY RESULTS OF PHASE III STUDY (STUDY 301) OF ANTICANCER AGENT HALAVEN® VERSUS CAPECITABINE IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
July 9, 2012 Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted
July 4, 2012 EISAI ANNOUNCES LAUNCH OF CHOCOLA BB® FRESH II, A NUTRITIONAL VITAMIN DRINK TO RELIEVE FATIGUE
July 3, 2012 EISAI RECEIVES EMA APPROVAL TO MARKET ZONEGRAN® MONOTHERAPY FOR TREATMENT OF EPILEPSY
July 3, 2012 EMA ACCEPTS EISAI'S LICENSE EXTENSION APPLICATION FOR USE OF ANTIEPILEPTC AGENT ZONEGRAN® IN PEDIATRIC PATIENTS
June 29, 2012 Eisai and Toyama Chemical Receive Approval to Market Anti-rheumatic Agent Iguratimod in Japan
June 28, 2012 U.S. FDA APPROVES ANTIOBESITY AGENT BELVIQ®(lorcaserin HCl) for Adults
First Prescription Weight-Loss Treatment Approved in U.S. in 13 Years
June 27, 2012 EISAI RECEIVES RUSSIAN REGULATORY APPROVAL FOR FIRST PRODUCT-ANTIEPILEPTIC AGENT ZONEGRAN®
June 22, 2012 Lyrica® Capsules Approved in Japan for Additional Indication of Pain Associated with Fibromyalgia
June 21, 2012 Notice on Allocation of Stock Options (Stock Acquisition Rights)
May 31, 2012 EISAI SEEKS APPROVAL TO MARKET PARIET® TRIPLE FORMULATION PACK IN JAPAN FOR HELICOBACTER PYLORI ERADICATION
May 28, 2012 EISAI GAINS POSITIVE CHMP OPINION FOR AMPA RECEPTOR ANTAGONIST FYCOMPATM (PERAMPANEL)
May 28, 2012 EISAI RECEIVES POSITIVE CHMP OPINION FOR ZONEGRAN® (ZONISAMIDE) MONOTHERAPY TREATMENT FOR EPILEPSY
May 25, 2012 SANNOVA RECEIVES APPROVAL FOR ADDITIONAL INDICATION, ADDITIONAL DOSAGE AND ADMINSITRATION OF KAYTWO® SYRUP 0.2% FOR PREVENTION OF VITAMIN K DEFICIENCY HEMORRHAGE IN NEONATES AND INFANTS
May 22, 2012 EISAI LAUNCHES NEW MOBILE WEBSITE TO SUPPORT REFLUX ESOPHAGITIS PATIENTS IN TAKING THEIR MEDICATION
May 18, 2012 EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCT PORTFOLIO AND PIPELINE AT 48th ASCO ANNUAL MEETING
May 15, 2012 Proposed Changes in Representative Officers
May 15, 2012 Issuance of Stock Acquisition Rights for the Purpose of Granting Stock Options to the Company's Employees
May 11, 2012 EISAI INC. EXPANDS MARKETING AND SUPPLY AGREEMENT WITH ARENA FOR ANTI-OBESITY AGENT LORCASERIN
May 11, 2012 ANTI-OBESITY AGENT LORCASERIN RECEIVES POSITIVE VOTE FROM FDA ADVISORY COMMITTEE
May 2, 2012 EISAI'S US RESEARCH SUBSIDIARY H3 BIOMEDICINE TO COLLOBORATE WITH UK-BASED HORIZON DISCOVERY TO IDENTIFY AND VALIDATE NOVEL, PATIENT-RELEVANT CANCER TARGETS
April 23, 2012 GERMAN FEDERAL REGULATOR CONFIRMS ADDITIONAL BENEFIT OF ANTICANCER AGENT HALAVEN® FOR METASTATIC OR LOCALLY ADVANCED BREAST CANCER
April 23, 2012 Abbott Japan and Eisai have Cleared the Condition for Approval of Humira®, a Fully Human Anti-TNF-α Monoclonal Antibody, for Plaque Psoriasis and Psoriasis Arthropica in Terms of the All-Case Surveillance
April 20, 2012 EISAI AMENDS LICENSE AGREEMENT WITH TEIKOKU PHARMA USA FOR ARICEPT® TRANSDERMAL PATCH SYSTEM
April 17, 2012 EISAI TO LAUNCH INSOMNIA TREATMENT LUNESTA® IN JAPAN
April 5, 2012 EISAI ENTERS INTO PARTNERSHIP WITH PHARMASWISS FOR HALAVEN® (ERIBULIN) PROMOTION AND DISTRIBUTION IN CENTRAL AND EASTERN EUROPEAN (CEE) COUNTRIES
April 3, 2012 Eisai Diagnostics Subsidiary EIDIA Enters Into Sales Agreements with Medical Equipment Manufacturers for PROTOCO2L Carbon Dioxide Insufflation System for CT Colonography
April 2, 2012 Eisai and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe, etc.
March 29, 2012 Notice Concerning Shelf Registration for Issuance of Stock Options
March 7, 2012 EISAI RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR DNA METHYLATION INHIBITOR DACOGEN® FOR INJECTION sNDA IN ACUTE MYELOID LEUKEMIA
March 6, 2012 U.S. FDA ACCEPTS RESUBMISSION OF AMPA RECEPTOR ANTAGONIST PERAMPANEL (E2007) NEW DRUG APPLICATION
February 9, 2012 Notice Regarding Transfer of Shares of Eisai Subsidiaries
January 30, 2012 EISAI INCREASES ITS COMMITMENT TO FIGHT
NEGLECTED TROPICAL DISEASES
-Two Innovative Programs Will Help Eliminate Lymphatic Filariasis By 2020-
January 20, 2012 MHLW APPROVES PARTIAL LABEL CHANGE FOR
EGG WHITE LYSOZYME PREPARATION NEUZYM®,
DESIGNATES DRUG FOR REEVALUATION
January 19, 2012 Eisai and EIDIA Announce Launch of LIFE CHECK,
a Self-monitoring Blood Glucose Meter That is Easy for
Elderly Diabetes Patients to Use
January 18, 2012 EISAI RECEIVES APPROVAL TO MARKET INSOMNIA TREATMENT
LUNESTA® IN JAPAN
January 16, 2012 Nobelpharma and Eisai Announce Japan Launch of Anticonvulsant Agent
Fostoin® 750 mg for Injection
January 5, 2012 ARENA SUBMITS RESPONSE TO
FDA COMPLETE RESPONSE LETTER FOR LORCASERIN

Back to Top